ý | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 77-0154833 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Large Accelerated filer | ý | Accelerated filer | ¨ | |||
Non-accelerated filer | o | Smaller reporting company | ¨ | |||
Emerging growth company | o |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.001 par value per share | BABY | The Nasdaq Stock Market LLC (The Nasdaq Global Market) |
Page No. | ||
Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 (unaudited) | ||
Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (unaudited) | ||
Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2019 and 2018 (unaudited) | ||
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited) | ||
March 31, 2019 | December 31, 2018 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 53,423 | $ | 56,373 | |||
Accounts receivable, net of allowance for doubtful accounts of $7,451 in 2019 and $6,960 in 2018 | 110,900 | 127,041 | |||||
Inventories | 82,866 | 79,736 | |||||
Prepaid expenses and other current assets | 26,793 | 22,625 | |||||
Total current assets | 273,982 | 285,775 | |||||
Property and equipment, net | 26,280 | 22,913 | |||||
Operating lease right-of-use assets | 18,982 | — | |||||
Intangible assets, net | 132,205 | 139,453 | |||||
Goodwill | 147,390 | 147,644 | |||||
Deferred income tax | 19,165 | 22,639 | |||||
Other assets | 20,559 | 19,716 | |||||
Total assets | $ | 638,563 | $ | 638,140 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 25,103 | $ | 28,805 | |||
Current portion of long-term debt | 35,000 | 35,000 | |||||
Accrued liabilities | 51,157 | 52,568 | |||||
Deferred revenue | 19,017 | 17,073 | |||||
Current portion of operating lease liabilities | 6,251 | — | |||||
Liabilities and accrued impairment held for sale | 24,786 | — | |||||
Total current liabilities | 161,314 | 133,446 | |||||
Long-term liabilities: | |||||||
Other liabilities | 21,325 | 19,845 | |||||
Operating lease liabilities | 15,234 | — | |||||
Long-term debt, net | 64,522 | 69,474 | |||||
Deferred income tax | 8,467 | 16,931 | |||||
Total liabilities | 270,862 | 239,696 | |||||
Stockholders’ equity: | |||||||
Common stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding 33,955,077 in 2019 and 33,804,379 in 2018 | 335,348 | 334,215 | |||||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and 2019 | — | — | |||||
Retained earnings | 73,592 | 102,261 | |||||
Accumulated other comprehensive loss | (41,239 | ) | (38,032 | ) | |||
Total stockholders’ equity | 367,701 | 398,444 | |||||
Total liabilities and stockholders’ equity | $ | 638,563 | $ | 638,140 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Revenue | $ | 114,757 | $ | 128,609 | |||
Cost of revenue | 46,370 | 55,369 | |||||
Intangibles amortization | 1,756 | 1,587 | |||||
Gross profit | 66,631 | 71,653 | |||||
Operating expenses: | |||||||
Marketing and selling | 33,729 | 35,872 | |||||
Research and development | 13,058 | 15,443 | |||||
General and administrative | 16,305 | 17,448 | |||||
Intangibles amortization | 3,786 | 4,806 | |||||
Restructuring | 37,372 | 812 | |||||
Total operating expenses | 104,250 | 74,381 | |||||
Loss from operations | (37,619 | ) | (2,728 | ) | |||
Other expense, net | (2,112 | ) | (1,821 | ) | |||
Loss before benefit from income tax | (39,731 | ) | (4,549 | ) | |||
Benefit from income tax | (9,730 | ) | (1,401 | ) | |||
Net loss | $ | (30,001 | ) | $ | (3,148 | ) | |
Foreign currency translation adjustment | (1,875 | ) | 3,617 | ||||
Comprehensive income (loss) | (31,876 | ) | 469 | ||||
Loss per share: | |||||||
Basic | $ | (0.89 | ) | $ | (0.10 | ) | |
Diluted | $ | (0.89 | ) | $ | (0.10 | ) | |
Weighted average shares used in the calculation of loss per share: | |||||||
Basic | 33,590 | 32,760 | |||||
Diluted | 33,590 | 32,760 |
Common Stock | Retained Earnings | Accumulated Other Comprehensive Loss | Stockholders’ Equity | |||||||||||||||
Shares | Amount | |||||||||||||||||
Balances, December 31, 2018 | 33,804,379 | $ | 334,215 | $ | 102,261 | $ | (38,032 | ) | $ | 398,444 | ||||||||
Reclassification of stranded tax effects for ASU 2018-02 | — | — | 1,332 | (1,332 | ) | — | ||||||||||||
Vesting of restricted stock units | 42,130 | — | — | — | — | |||||||||||||
Net issuance of restricted stock awards | 139,718 | — | — | — | — | |||||||||||||
Stock-based compensation expense | — | 2,432 | — | — | 2,432 | |||||||||||||
Taxes paid related to net share settlement of equity awards | (47,767 | ) | (1,567 | ) | — | — | (1,567 | ) | ||||||||||
Exercise of stock options | 16,617 | 268 | — | — | 268 | |||||||||||||
Other comprehensive loss | — | — | — | (1,875 | ) | (1,875 | ) | |||||||||||
Net loss | — | — | (30,001 | ) | — | (30,001 | ) | |||||||||||
Balances, March 31, 2019 | 33,955,077 | $ | 335,348 | $ | 73,592 | $ | (41,239 | ) | $ | 367,701 |
Common Stock | Retained Earnings | Accumulated Other Comprehensive Loss | Stockholders’ Equity | |||||||||||||||
Shares | Amount | |||||||||||||||||
Balances, December 31, 2017 | 33,134,101 | $ | 316,577 | $ | 129,115 | $ | (23,595 | ) | $ | 422,097 | ||||||||
Cumulative-effect adjustment for ASU 2016-16 | — | — | (3,919 | ) | — | (3,919 | ) | |||||||||||
Vesting of restricted stock units | 100 | — | — | — | — | |||||||||||||
Net issuance of restricted stock awards | 239,649 | — | — | — | — | |||||||||||||
Stock-based compensation expense | — | 2,361 | — | — | 2,361 | |||||||||||||
Repurchase of company stock | (147,893 | ) | (4,736 | ) | — | — | (4,736 | ) | ||||||||||
Taxes paid related to net share settlement of equity awards | (600 | ) | (19 | ) | — | — | (19 | ) | ||||||||||
Exercise of stock options | 46,173 | 577 | — | — | 577 | |||||||||||||
Other comprehensive income | — | — | — | 3,617 | 3,617 | |||||||||||||
Net loss | — | — | (3,148 | ) | — | (3,148 | ) | |||||||||||
Balances, March 31, 2018 | 33,271,530 | $ | 314,760 | $ | 122,048 | $ | (19,978 | ) | $ | 416,830 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Operating activities: | |||||||
Net loss | $ | (30,001 | ) | $ | (3,148 | ) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
Provision for losses on accounts receivable | 600 | 918 | |||||
Depreciation and amortization | 7,711 | 7,915 | |||||
Loss on disposal of property and equipment | 179 | 52 | |||||
Warranty reserve | 354 | (1,125 | ) | ||||
Share-based compensation | 2,554 | 2,362 | |||||
Impairment charge on held for sale entity | 24,571 | — | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 15,555 | (2,242 | ) | ||||
Inventories | (4,616 | ) | 2,885 | ||||
Prepaid expenses and other assets | (7,703 | ) | (5,390 | ) | |||
Accounts payable | (3,436 | ) | (622 | ) | |||
Accrued liabilities | (1,319 | ) | 3,319 | ||||
Deferred revenue | 1,982 | 1,314 | |||||
Deferred income tax | 62 | 87 | |||||
Net cash provided by operating activities | 6,493 | 6,325 | |||||
Investing activities: | |||||||
Purchase of property and equipment | (2,461 | ) | (2,473 | ) | |||
Net cash used in investing activities | (2,461 | ) | (2,473 | ) | |||
Financing activities: | |||||||
Proceeds from stock option exercises and Employee Stock Purchase Program purchases | 268 | 577 | |||||
Repurchase of common stock | — | (4,736 | ) | ||||
Taxes paid related to net share settlement of equity awards | (1,567 | ) | (19 | ) | |||
Principal payments of financing lease liability | (165 | ) | — | ||||
Payment of contingent consideration related to a business combination | — | (147 | ) | ||||
Payments on borrowings | (5,000 | ) | (25,000 | ) | |||
Net cash used in financing activities | (6,464 | ) | (29,325 | ) | |||
Exchange rate changes effect on cash and cash equivalents | (518 | ) | 994 | ||||
Net decrease in cash and cash equivalents | (2,950 | ) | (24,479 | ) | |||
Cash and cash equivalents, beginning of period | 56,373 | 88,950 | |||||
Cash and cash equivalents, end of period | $ | 53,423 | $ | 64,471 | |||
Supplemental disclosure of cash flow information: | |||||||
Cash paid for interest | $ | 1,347 | $ | 1,482 | |||
Cash paid for income taxes | $ | 1,224 | $ | 1,657 | |||
Non-cash investing activities: | |||||||
Property and equipment included in accounts payable | $ | 141 | $ | 349 | |||
Inventory transferred to property and equipment | $ | 143 | $ | 161 |
• | Management approves and commits to a formal plan to sell the asset or disposal group; |
• | The assets or disposal group is available for immediate sale in its present condition; |
• | An active program to locate a buyer and other actions required to complete the sale have been initiated; |
• | The sale of the asset or disposal group is expected to be completed within one year; |
• | The asset or disposal group is being actively marketed for sale at a price that is reasonable in relation to the current fair value; and |
• | It is unlikely that significant changes will be made to the plan. |
Unbilled AR, December 31, 2018 | $ | 3,012 | |
Additions | 26 | ||
Transferred to Trade Receivable | (495 | ) | |
Unbilled AR, March 31, 2019 | $ | 2,543 |
Deferred Revenue, December 31, 2018 | $ | 21,410 | |
Additions | 9,143 | ||
Revenue Recognized | (7,164 | ) | |
Deferred Revenue, March 31, 2019 | $ | 23,389 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Net loss | $ | (30,001 | ) | $ | (3,148 | ) | |
Weighted average common shares | 33,590 | 32,760 | |||||
Dilutive effect of stock based awards | — | — | |||||
Diluted Shares | 33,590 | 32,760 | |||||
Basic loss per share | $ | (0.89 | ) | $ | (0.10 | ) | |
Diluted loss per share | $ | (0.89 | ) | $ | (0.10 | ) | |
Shares excluded from calculation of diluted EPS | 119 | 390 |
March 31, 2019 | December 31, 2018 | ||||||
Raw materials and subassemblies | $ | 36,107 | $ | 31,459 | |||
Work in process | 2,424 | 2,424 | |||||
Finished goods | 63,277 | 63,932 | |||||
Total inventories | 101,808 | 97,815 | |||||
Less: Non-current inventories | (18,942 | ) | (18,079 | ) | |||
Inventories, current | $ | 82,866 | $ | 79,736 |
March 31, 2019 | December 31, 2018 | ||||||||||||||||||||||||||||||
Gross Carrying Amount | Accumulated Impairment | Accumulated Amortization | Net Book Value | Gross Carrying Amount | Accumulated Impairment | Accumulated Amortization | Net Book Value | ||||||||||||||||||||||||
Intangible assets with definite lives: | |||||||||||||||||||||||||||||||
Technology | $ | 110,161 | $ | (6,630 | ) | $ | (51,387 | ) | $ | 52,144 | $ | 111,198 | $ | (6,768 | ) | $ | (50,046 | ) | $ | 54,384 | |||||||||||
Customer related | 98,403 | (50 | ) | (42,160 | ) | 56,193 | 99,440 | (1,961 | ) | (38,574 | ) | 58,905 | |||||||||||||||||||
Trade names | 46,875 | (3,812 | ) | (21,161 | ) | 21,902 | 47,217 | (4,397 | ) | (19,250 | ) | 23,570 | |||||||||||||||||||
Internally developed software | 16,266 | — | (14,670 | ) | 1,596 | 16,264 | — | (14,164 | ) | 2,100 | |||||||||||||||||||||
Patents | 2,937 | (132 | ) | (2,765 | ) | 40 | 2,718 | (133 | ) | (2,524 | ) | 61 | |||||||||||||||||||
Service Agreements | 1,190 | — | (860 | ) | 330 | 1,190 | — | (757 | ) | 433 | |||||||||||||||||||||
Definite-lived intangible assets | $ | 275,832 | $ | (10,624 | ) | $ | (133,003 | ) | $ | 132,205 | $ | 278,027 | $ | (13,259 | ) | $ | (125,315 | ) | $ | 139,453 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Technology | $ | 1,738 | $ | 1,819 | |||
Customer related | 2,183 | 2,881 | |||||
Trade names | 1,498 | 1,626 | |||||
Internally developed software | 504 | 530 | |||||
Patents | 20 | 22 | |||||
Service Agreements | 102 | — | |||||
Total amortization | $ | 6,045 | $ | 6,878 |
Nine months ending December 31, 2019 | $ | 17,250 | |
2020 | 21,678 | ||
2021 | 20,791 | ||
2022 | 17,349 | ||
2023 | 16,378 | ||
2024 | 14,487 | ||
Thereafter | 24,272 | ||
Total expected amortization expense | $ | 132,205 |
December 31, 2018 | $ | 147,644 | |
Foreign currency translation | (254 | ) | |
March 31, 2019 | $ | 147,390 |
March 31, 2019 | December 31, 2018 | ||||||
Land | $ | 1,677 | $ | 1,828 | |||
Buildings | 6,184 | 7,036 | |||||
Leasehold improvements | 4,703 | 4,649 | |||||
Finance lease right-of-use assets | 3,064 | — | |||||
Equipment and furniture | 26,879 | 23,487 | |||||
Computer software and hardware | 12,936 | 12,803 | |||||
Demonstration and loaned equipment | 12,646 | 12,843 | |||||
68,089 | 62,646 | ||||||
Accumulated depreciation | (41,809 | ) | (39,733 | ) | |||
Total | $ | 26,280 | $ | 22,913 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Balance, beginning of period | $ | 9,391 | $ | 10,995 | |||
Additions charged to expense | 609 | (1,125 | ) | ||||
Utilizations | (1,511 | ) | (802 | ) | |||
Changes in estimate related to product remediation activities | (255 | ) | — | ||||
Divestiture adjustments | (9 | ) | — | ||||
Balance, end of period | $ | 8,225 | $ | 9,068 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Cost of revenue | $ | 67 | $ | 68 | |||
Marketing and selling | 230 | 198 | |||||
Research and development | 245 | 276 | |||||
General and administrative | 1,890 | 1,820 | |||||
Total | $ | 2,432 | $ | 2,362 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Interest income | $ | 20 | $ | 10 | |||
Interest expense | (1,527 | ) | (1,960 | ) | |||
Foreign currency gain (loss) | (598 | ) | 604 | ||||
Other expense | (7 | ) | (475 | ) | |||
Total other expense, net | $ | (2,112 | ) | $ | (1,821 | ) |
• | Leverage Ratio, as defined, to be no higher than 2.75 to 1.00. |
• | Interest Coverage Ratio, as defined, to be at least 1.75 to 1.00 at all times. |
March 31, 2019 | December 31, 2018 | ||||||
Revolving credit facility | $ | 100,000 | $ | 105,000 | |||
Debt issuance costs | (478 | ) | (526 | ) | |||
Less: current portion of long-term debt | 35,000 | 35,000 | |||||
Total long-term debt | $ | 64,522 | $ | 69,474 |
March 31, 2019 | December 31, 2018 | ||||||
2019 | $ | — | $ | — | |||
2020 | — | — | |||||
2021 | 100,000 | 105,000 | |||||
Thereafter | — | — | |||||
Total | $ | 100,000 | $ | 105,000 |
Hedged Item | Current Notional Amount | Designation Date | Effective Date | Termination Date | Fixed Interest Rate | Floating Rate | Estimated Fair Value | ||||
1-month USD LIBOR Loan | $ | 40,000 | May 31, 2018 | June 1, 2018 | September 23, 2021 | 2.611% | 1-month USD LIBOR | $ | 179 | ||
Total interest rate derivatives designated as cash flow hedge | $ | 40,000 | $ | 179 |
Three Months Ended March 31, | |||
2019 | |||
Operating lease cost | $ | 1,765 | |
Finance lease cost: | |||
Amortization of right-of-use assets (principal payments) | 165 | ||
Interest on lease liabilities | 22 | ||
Short-term lease cost | 38 | ||
Variable lease cost | 884 | ||
Sublease income | (34 | ) | |
Total lease cost | $ | 2,840 |
Three Months Ended March 31, | |||
2019 | |||
Cash paid for amounts included in the measurement of lease liabilities: | |||
Operating cash flows from operating leases | $ | 3,493 | |
Operating cash flows from finance leases | 37 | ||
Financing cash flows from finance leases | 165 | ||
Right-of-use assets obtained in exchange for lease obligations: | |||
Operating leases | 1,120 | ||
Finance leases | 87 |
March 31, 2019 | |||
Operating Leases | |||
Operating lease right-of-use assets | $ | 18,982 | |
Accrued liabilities | $ | 6,251 | |
Operating lease liabilities | 15,234 | ||
Total operating lease liabilities | $ | 21,485 | |
Finance Leases | |||
Property and equipment, gross | $ | 3,064 | |
Accumulated amortization | 1,537 | ||
Property and equipment, net | $ | 1,527 | |
Accrued liabilities | $ | 563 | |
Other liabilities | 1,023 | ||
Total finance lease liabilities | $ | 1,586 | |
Weighted Average Remaining Lease Term | |||
Operating leases | 4.1 years | ||
Finance leases | 3.7 years | ||
Weighted Average Discount Rate | |||
Operating leases | 5.3 | % | |
Finance leases | 5.1 | % |
Year ending December 31, | Operating Leases | Finance Leases | |||||
2019 | $ | 6,925 | $ | 609 | |||
2020 | 5,850 | 486 | |||||
2021 | 4,414 | 370 | |||||
2022 | 2,850 | 167 | |||||
2023 | 2,190 | 42 | |||||
Thereafter | 1,121 | — | |||||
Total lease payments | 23,350 | 1,674 | |||||
Less imputed interest | (1,865 | ) | (88 | ) | |||
Total | $ | 21,485 | $ | 1,586 |
Year ending December 31, | Operating Leases | ||
2019 | $ | 8,092 | |
2020 | 6,951 | ||
2021 | 5,290 | ||
2022 | 3,423 | ||
2023 | 2,426 | ||
Thereafter | 1,365 | ||
Total minimum lease payments | $ | 27,547 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Consolidated Revenue: | |||||||
United States | $ | 66,067 | $ | 68,671 | |||
International | 48,690 | 59,938 | |||||
Totals | $ | 114,757 | $ | 128,609 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Revenue by End Market: | |||||||
Neurology Products | |||||||
Devices and Systems | $ | 45,749 | $ | 46,041 | |||
Supplies | 15,841 | 17,172 | |||||
Services | 800 | 2,737 | |||||
Total Neurology Revenue | 62,390 | 65,950 | |||||
Newborn Care Products | |||||||
Devices and Systems | 12,711 | 15,966 | |||||
Supplies | 9,323 | 9,522 | |||||
Services | 4,845 | 5,403 | |||||
Total Newborn Care Revenue | 26,879 | 30,891 | |||||
Audiology Products | |||||||
Devices and Systems | 23,459 | 29,523 | |||||
Supplies | 2,029 | 2,245 | |||||
Total Audiology Revenue | 25,488 | 31,768 | |||||
Total Revenue | $ | 114,757 | $ | 128,609 |
March 31, 2019 | December 31, 2018 | ||||||
Property and equipment, net: | |||||||
United States | $ | 13,177 | $ | 10,019 | |||
Ireland | 5,419 | 5,083 | |||||
Canada | 4,543 | 4,504 | |||||
Denmark | 1,952 | 1,371 | |||||
Argentina | — | 999 | |||||
Other countries | 1,189 | 937 | |||||
Totals | $ | 26,280 | $ | 22,913 |
December 31, 2018 | Additions | Payments | Adjustments | March 31, 2019 | |||||||||||||||
Liabilities: | |||||||||||||||||||
Interest Rate Swap | $ | 77 | $ | — | $ | — | $ | 102 | $ | 179 | |||||||||
Total | $ | 77 | $ | — | $ | — | $ | 102 | $ | 179 |
• | Neuro - Includes products and services that provide diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery. Neuro's comprehensive neurodiagnostic solutions include electroencephalography and long term monitoring, Intensive Care Unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring. |
• | Newborn Care - Includes products and services for newborn care including hearing screening, brain injury, ROP vision screening, thermoregulation, jaundice management, and various disposable newborn care supplies, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. |
• | Audiology - Includes products hearing and diagnostics and hearing aid fitting, including computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals. Audiology has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets. Global brands include Aurical®, ICS®, and Madsen®. |
Three Months Ended March 31, | |||||
2019 | 2018 | ||||
Devices and Systems | 71 | % | 71 | % | |
Supplies | 24 | % | 23 | % | |
Services | 5 | % | 6 | % | |
Total | 100 | % | 100 | % |
• | Revenue recognition |
• | Income taxes |
• | Inventory valuation |
Three Months Ended March 31, | |||||
2019 | 2018 | ||||
Revenue | 100.0 | % | 100.0 | % | |
Cost of revenue | 40.4 | % | 43.1 | % | |
Intangibles amortization | 1.5 | % | 1.2 | % | |
Gross profit | 58.1 | % | 55.7 | % | |
Operating expenses: | |||||
Marketing and selling | 29.4 | % | 27.9 | % | |
Research and development | 11.4 | % | 12.0 | % | |
General and administrative | 14.2 | % | 13.6 | % | |
Intangibles amortization | 3.3 | % | 3.7 | % | |
Restructuring | 32.6 | % | 0.6 | % | |
Total operating expenses | 90.9 | % | 57.8 | % | |
Loss from operations | (32.8 | )% | (2.1 | )% | |
Other expense, net | (1.9 | )% | (1.4 | )% | |
Loss before benefit from income tax | (34.7 | )% | (3.5 | )% | |
Benefit from income tax | (8.5 | )% | (1.1 | )% | |
Net loss | (26.2 | )% | (2.4 | )% |
Three Months Ended March 31, | ||||||||||
2019 | 2018 | Change | ||||||||
Neuro Products | ||||||||||
Devices and Systems | $ | 45,749 | $ | 46,041 | (1 | )% | ||||
Supplies | 15,841 | 17,172 | (8 | )% | ||||||
Services | 800 | 2,737 | (71 | )% | ||||||
Total Neurology Revenue | 62,390 | 65,950 | (5 | )% | ||||||
Newborn Care Products | ||||||||||
Devices and Systems | 12,711 | 15,966 | (20 | )% | ||||||
Supplies | 9,323 | 9,522 | (2 | )% | ||||||
Services | 4,845 | 5,403 | (10 | )% | ||||||
Total Newborn Care Revenue | 26,879 | 30,891 | (13 | )% | ||||||
Audiology Products | ||||||||||
Devices and Systems | 23,459 | 29,523 | (21 | )% | ||||||
Supplies | 2,029 | 2,245 | (10 | )% | ||||||
Total Audiology Revenue | 25,488 | 31,768 | (20 | )% | ||||||
Total Revenue | $ | 114,757 | $ | 128,609 | (11 | )% |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Revenue | $ | 114,757 | $ | 128,609 | |||
Cost of revenue | 46,370 | 55,369 | |||||
Intangibles amortization | 1,756 | 1,587 | |||||
Gross profit | 66,631 | 71,653 | |||||
Gross profit percentage | 58.1 | % | 55.7 | % |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Marketing and selling | $ | 33,729 | $ | 35,872 | |||
Percentage of revenue | 29.4 | % | 27.9 | % | |||
Research and development | $ | 13,058 | $ | 15,443 | |||
Percentage of revenue | 11.4 | % | 12.0 | % | |||
General and administrative | $ | 16,305 | $ | 17,448 | |||
Percentage of revenue | 14.2 | % | 13.6 | % | |||
Intangibles amortization | $ | 3,786 | $ | 4,806 | |||
Percentage of revenue | 3.3 | % | 3.7 | % | |||
Restructuring | $ | 37,372 | $ | 812 | |||
Percentage of revenue | 32.6 | % | 0.6 | % |
March 31, 2019 | December 31, 2018 | ||||||
Cash and cash equivalents | $ | 53,423 | $ | 56,373 | |||
Working capital | 112,668 | 152,329 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Net cash provided by operating activities | $ | 6,493 | $ | 6,325 | |||
Net cash used in investing activities | (2,461 | ) | (2,473 | ) | |||
Net cash used in financing activities | (6,464 | ) | (29,325 | ) |
• | Extent to which we make acquisitions; |
• | Amount and timing of revenue; |
• | Extent to which our existing and new products gain market acceptance; |
• | Cost and timing of product development efforts and the success of these development efforts; |
• | Cost and timing of marketing and selling activities; and |
• | Availability of borrowings under line of credit arrangements and the availability of other means of financing. |
Payments Due by Period | |||||||||||||||||||
Total | Less than 1 Year | 1-3 Years | 3-5 Years | More than 5 Years | |||||||||||||||
Unconditional purchase obligations | $ | 63,813 | $ | 61,865 | $ | 1,948 | $ | — | $ | — | |||||||||
Bank debt | 100,000 | — | 100,000 | — | — | ||||||||||||||
Interest payments | 7,695 | 4,684 | 3,011 | ||||||||||||||||
Repatriation tax | 9,992 | 800 | 1,751 | 2,517 | 4,924 | ||||||||||||||
Total | $ | 181,500 | $ | 67,349 | $ | 106,710 | $ | 2,517 | $ | 4,924 |
(a) | Exhibits |
Incorporated By Reference | ||||||||||
Exhibit No. | Exhibit | Filing | Exhibit No. | File Date | Filed Herewith | |||||
X | ||||||||||
X | ||||||||||
X | ||||||||||
X | ||||||||||
101 | The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Income, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements. | X |
NATUS MEDICAL INCORPORATED | |||||
Dated: | May 8, 2019 | By: | /s/ Jonathan A. Kennedy | ||
Jonathan A. Kennedy President and Chief Executive Officer (Principal Executive Officer) | |||||
Dated: | May 8, 2019 | By: | /s/ B. Drew Davies | ||
B. Drew Davies Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
Date: | May 8, 2019 | |||||
/s/ Jonathan A. Kennedy | ||||||
Jonathan A. Kennedy | ||||||
President and Chief Executive Officer |
Date: | May 8, 2019 | |||||
/s/ B. Drew Davies | ||||||
B. Drew Davies | ||||||
Executive Vice President | ||||||
and Chief Financial Officer |
/s/ Jonathan A. Kennedy | |
Print Name: Jonathan A. Kennedy | |
Title: President and Chief Executive Officer | |
Date: | May 8, 2019 |
/s/ B. Drew Davies | |
Print Name: B. Drew Davies | |
Title: Executive Vice President and Chief Financial Officer | |
Date: | May 8, 2019 |
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
May 03, 2019 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | NATUS MEDICAL INC | |
Entity Central Index Key | 0000878526 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 34,005,780 |
Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 8,003 | $ 6,960 |
Common Stock, par value (dollars per share) | $ 0.001 | $ 0.001 |
Common Stock, shares authorized (in shares) | 120,000,000 | 120,000,000 |
Common Stock, shares issued (in shares) | 33,955,077 | 33,804,379 |
Common Stock, shares outstanding (in shares) | 33,955,077 | 33,804,379 |
Preferred Stock, par value (dollars per share) | $ 0.001 | $ 0.001 |
Preferred Stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred Stock, shares issued (in shares) | 0 | 0 |
Preferred Stock, shares outstanding (in shares) | 0 | 0 |
Basis of Presentation |
3 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||
Basis of Presentation | Basis of Presentation and Significant Accounting Policies The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (“Natus,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Except where noted below within Note 1, the accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, the reports do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, and reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. The consolidated balance sheet as of December 31, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Recent Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02. The new standard provides a number of optional practical expedients in transition. The Company elected the 'package of practical expedients,' which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company has not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to the Company. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off the balance sheet. The Company will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term. The new standard became effective for the Company on January 1, 2019. The Company adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, the Company recognized additional new lease assets of approximately $19.5 million and additional lease liabilities of approximately $22.3 million as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance will not be updated and the disclosures required under the new standard will not be provided for periods prior to January 1, 2019. The adoption of the new standard did not impact the Company's liquidity or debt-covenant compliance under its current agreements. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “2017 Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU is effective for the Company on January 1, 2019. Upon adoption, the Company reclassified its stranded tax effects resulting from the 2017 Act of $1.3 million, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019. In July 2018, the FASB issued ASU 2018-09, Codification Improvements. This update makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standard Codification. The majority of the amendments in ASU 2018-09 will be effective for us in annual periods beginning after December 15, 2018. The adoption of this guidance did not have an impact on the Company's consolidated financial statements. Recent Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Credit Losses (Topic 326). This update requires financial assets measured at amortized cost, such as trade receivables and contract assets, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The guidance is effective beginning January 1, 2020. The Company is evaluating the impact, if any, that this pronouncement will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for the Company's annual and any interim goodwill impairment tests performed on or after January 1, 2020. The Company does not expect the adoption of ASU 2017-04 to have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement (Topic 813), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. This update amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosure. For calendar year-end entities, the update will be effective for annual periods beginning January 1, 2020, and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period. As the standard relates only to disclosures, the Company does not expect the adoption to have a material impact on the consolidated financial statements and is still evaluating if it will early adopt. Significant Accounting Policies Leases The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit borrowing rate, an incremental borrowing rate is used in determining the present value of lease payments based on information available at commencement date. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term. Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in the Company's consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet. The Company has lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, the Company accounts for these components separately. For equipment leases, such as office equipment and vehicles, the Company accounts for the lease and non-lease components as a single lease component. Assets and Liabilities Held for Sale The Company considers assets and liabilities to be held for sale when all of the following criteria are met:
Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, the Company records the asset or disposal group at the lower of it carrying value or its estimated fair value, less estimated costs of sale. The Company considers deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on the Company's income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. The Company assesses the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and reports any reduction in fair value as an adjustment to the carrying value of the assets held for sale. |
Revenue (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Revenue | Revenue Unbilled accounts receivable (“AR”) for the periods presented primarily represent the difference between revenue recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to extended service contracts, installation, and training, for which the service fees are billed up-front. The associated deferred revenue is generally recognized ratably over the extended service period or when installation and training are complete. The following table summarizes the changes in the unbilled AR and deferred revenue balances for the three months ended March 31, 2019 (in thousands):
At March 31, 2019, the short-term portion of deferred revenue of $19.0 million and the long-term portion of $4.4 million were included in deferred revenue and other long term liabilities respectively, in the consolidated balance sheet. As of March 31, 2019, the Company expects to recognize revenue associated with deferred revenue of approximately $16.4 million in 2019, $4.4 million in 2020, $1.3 million in 2021, $0.8 million in 2022, and $0.5 million thereafter. |
Earnings Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share The components of basic and diluted EPS are as follows (in thousands, except per share amounts):
|
Inventories |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories Inventories consist of the following (in thousands):
As of March 31, 2019 and December 31, 2018, the Company has classified $18.9 million and $18.1 million, respectively, of inventories as other assets. This inventory consists primarily of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products the Company no longer sells, inventory purchased for lifetime buys, and inventory that is turning over at a slow rate. The Company believes these inventories will be utilized for their intended purpose. |
Intangible Assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets | Intangible Assets The following table summarizes the components of gross and net intangible asset balances (in thousands):
Finite-lived intangible assets are amortized over their weighted average lives, which are 14 years for technology, 10 years for customer related intangibles, 7 years for trade names, 6 years for internally developed software, 13 years for patents, 2 years for service agreements and 11 years weighted average in total. Internally developed software consists of $14.0 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold. Amortization expense related to intangible assets with definite lives was as follows (in thousands):
The amortization expense amounts shown above include internally developed software not held for sale of $459.0 thousand for the three months ended March 31, 2019 which is recorded within the Company's income statement as a general and administrative operating expense. Expected amortization expense related to amortizable intangible assets is as follows (in thousands):
|
Goodwill |
3 Months Ended | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||
Goodwill | Goodwill The carrying amount of goodwill and the changes in the balance are as follows (in thousands):
|
Property and Equipment, net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment, net | Property and Equipment, net Property and equipment, net consist of the following (in thousands):
Depreciation expense of property and equipment was approximately $1.5 million for the three months ended March 31, 2019 and approximately $1.0 million for the three months ended March 31, 2018. |
Reserve for Product Warranties |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Product Warranties Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserve for Product Warranties | Reserve for Product Warranties The Company provides a warranty for products that is generally one year in length, but in some cases regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, the Company may incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities, vendors on a contract basis, and distributors. A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations. As of March 31, 2019, the Company had accrued $3.2 million of estimated costs to bring certain products into U.S. regulatory compliance. The Company's estimate of these costs associated with bringing the products into compliance is primarily based upon the number of units outstanding that may require repair, costs associated with shipping, and the assumption the FDA will approve the Company's plan for compliance. The details of activity in the warranty reserve are as follows (in thousands):
The estimates the Company uses in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations. |
Share-Based Compensation |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation | Share-Based Compensation As of March 31, 2019, the Company has two active share-based compensation plans, the 2018 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan. In January 2019, the Company granted market stock unit (“MSU”) awards to certain employees. These MSUs fully vest on December 31, 2021 and have separate market performance goals than the performance stock unit (“PSU”) awards the Company grants. Each MSU represents the right to one share of common stock. The actual number of MSUs which will be eligible to vest will be based on the performance of Natus' stock price over the vesting period. The maximum number of MSUs which will be eligible to vest are 200% of the MSUs initially granted. The Company used a third-party service provider to estimate the fair value of the MSUs at their grant date using a Monte Carlo simulation model. This model simulates the stock price movements of the Company using certain assumptions, including the stock price of the company. The terms of all other awards granted during the three months ended March 31, 2019 and the methods for determining grant-date fair value of the awards are consistent with those described in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. Details of share-based compensation expense are as follows (in thousands):
As of March 31, 2019, unrecognized compensation expense related to the unvested portion of stock options and other stock awards was approximately $15.0 million, which is expected to be recognized over a weighted average period of 2.5 years. |
Other Income (Expense), net |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income (Expense), net | Other Income (Expense), net Other income (expense), net consists of (in thousands):
|
Income Taxes |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company's tax provision for interim periods is determined using an estimated annual effective tax rate, adjusted for discrete events arising in each respective quarter. During each interim period, the Company updates the estimated annual effective tax rate which is subject to significant volatility due to several factors, including the Company's ability to accurately predict the income (loss) before provision for income taxes in multiple jurisdictions, the effects of acquisitions, the integration of those acquisitions, and changes in tax law. In circumstances where the Company is unable to predict income (loss) in multiple jurisdictions, the actual year to date effective tax rate may be the best estimate of the annual effective tax rate for purposes of determining the interim provision for income tax. The Company recorded a benefit from income tax of $9.7 million and a benefit from income tax of $1.4 million for the three months ended March 31, 2019 and March 31, 2018, respectively. Of the $9.7 million benefit from income tax recorded for the three months ended March 31, 2019, $8.2 million relates to the tax accounting effects of the planned divestiture of Medix. The effective tax rate was 24.5% and 30.8% for the three months ended March 31, 2019 and March 31, 2018, respectively. The decrease in the effective tax rate for the three months ended March 31, 2019 compared with the three months ended March 31, 2018 is primarily attributable to the tax accounting effects of the planned divestiture of Medix. The Company's effective tax rate for the three months ended March 31, 2019 differed from the federal statutory rate of 21% primarily due to the tax accounting effects of the planned divestiture of Medix. Other significant factors that impact the effective tax rate are Federal and California research and development credits, non-deductible executive compensation expenses, and inclusions related to global intangible low-taxed income. The Company recorded $0.2 million of net tax expense related to unrecognized tax benefits for the three months ended March 31, 2019, primarily due to the increase in uncertain tax positions related to the prior year. The Company reclassified $2.2 million of unrecognized tax benefits to long-term taxes payable as a result of the legislative developments in the current period. Within the next twelve months, it is possible that the uncertain tax benefit may change with a range of approximately zero to $3.8 million. The Company's tax returns remain open to examination as follows: U.S Federal, 2015 through 2018, U.S. States, 2014 through 2018, and significant foreign jurisdictions, generally 2014 through 2018. |
Debt and Credit Arrangements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt and Credit Arrangements | Debt and Credit Arrangements The Company has a Credit Agreement with JP Morgan Chase Bank ("JP Morgan"), Citibank, NA (“Citibank”), and Wells Fargo Bank, National Association (“Wells Fargo”). The Credit Agreement provides for an aggregate $225.0 million of secured revolving credit facility. The Credit Agreement contains covenants, including covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of the Company's assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company has no other significant credit facilities. In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require the Company to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:
At March 31, 2019, the Company was in compliance with the Leverage Ratio and the Interest Coverage Ratio covenants as defined in the Credit Agreement. At March 31, 2019, the Company had $100.0 million outstanding under the Credit Agreement. Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on our leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between 1.75% to 2.75%. The effective interest rate during the three months ended March 31, 2019 was 4.75%. The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable. Long-term debt consists of (in thousands):
Maturities of long-term debt as of March 31, 2019 are as follows (in thousands):
As of March 31, 2019, the carrying value of total debt approximated fair market value. |
Financial Instruments and Derivatives |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments and Derivatives | Financial Instruments and Derivatives The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings. The Company held the following interest rate swaps as of March 31, 2019 (in thousands):
The Company designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and records the change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax. Once the hedged item affects earnings, the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time. As of March 31, 2019, the Company expects that approximately $44.0 thousand of losses associated with the cash flow hedge, net of tax, could be reclassified from AOCI into earnings within the next twelve months. |
Leases (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases The Company has operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to eight years, some of which include options to extend the leases for up to ten years. The Company's leases do not have any residual value guarantees or any restrictions or covenants imposed by leases. Components of lease cost were as follows (in thousands):
Supplemental cash flow information related to leases was as follows (in thousands):
Supplemental balance sheet information related to leases was as follows (in thousands):
As of March 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
As the Company elected to apply the provisions of Topic 842 on a prospective basis, the following comparative period disclosure is being presented in accordance with Topic 840. The future minimum commitments under the Company’s leases as of December 31, 2018 were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases The Company has operating and finance leases for offices, warehouses, and certain equipment. The leases have remaining lease terms of one to eight years, some of which include options to extend the leases for up to ten years. The Company's leases do not have any residual value guarantees or any restrictions or covenants imposed by leases. Components of lease cost were as follows (in thousands):
Supplemental cash flow information related to leases was as follows (in thousands):
Supplemental balance sheet information related to leases was as follows (in thousands):
As of March 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
As the Company elected to apply the provisions of Topic 842 on a prospective basis, the following comparative period disclosure is being presented in accordance with Topic 840. The future minimum commitments under the Company’s leases as of December 31, 2018 were as follows (in thousands):
|
Segment, Customer and Geographic Information |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment, Customer and Geographic Information | Segment, Customer and Geographic Information The Company operates in one reportable segment in which the Company provides healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments. End-user customer base includes hospitals, clinics, laboratories, physicians, audiologists, and governmental agencies. Most of the Company's international sales are to distributors who resell products to end users or sub-distributors. Revenue and long-lived asset information are as follows (in thousands):
During the three months ended March 31, 2019 and 2018, no single customer or country outside the United States contributed more than 10% of the Company's consolidated revenue. |
Fair Value Measurements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The derivative financial instruments described in Note 13 are measured at fair value on a recurring basis and are presented on the consolidated balance sheets at fair value. The table below presents the fair value of the derivative financial instruments as well as the classification on the consolidated balance sheet (in thousands):
The Company estimates the fair value of the interest rate swaps by calculating the present value of the expected future cash flows of each swap. The calculation incorporated the contractual terms of the derivatives, observable market interest rates which are considered to be Level 2 inputs, and credit risk adjustments, if any, to reflect the counterpart's as well as the Company's nonperformance risk. As of March 31, 2019, there have been no events of default under the interest rate swap agreement. The following financial instruments are not measured at fair value on the Company’s consolidated balance sheet as of March 31, 2019 and December 31, 2018, but require disclosure of their fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of their relatively short maturity. |
Sale of Certain Subsidiary Assets Sale of Certain Subsidiary Assets |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Sale of Certain Subsidiary Assets | Sale of Certain Subsidiary Assets On January 15, 2019, the Company announced the implementation of a restructuring plan designed to improve operational performance, known as “One Natus.” As part of the restructuring, the Company identified its wholly owned subsidiary, Medix Medical Devices, SRL (“Medix”) as a targeted divestiture. Effective March 18, 2019, a letter of intent was executed that included the mutually agreed upon steps and details to effectuate the sale. The letter outlined the plan to sell Medix, including all of its assets and liabilities, to the local managing director via a stock sale. The transaction was finalized in the second quarter of 2019 when, on April 2, 2019, the Company signed the stock purchase agreement and completed the divestiture of Medix. The purchase price of the sale was $2,500 in cash and as part of the transaction, the Company provided a $2.2 million limited-recourse note to Medix, secured by certain assets of Medix, and whereby repayment is conditional upon the sale of those specific assets. As part of the transactions, the Company and the buyer also entered into an International Distributor Agreement whereby Medix will continue to distribute Natus products in addition to Medix and other third party products. The held for sale criteria under GAAP was met when the sale became probable on March 18, 2019. As such, the Company segregated the assets and liabilities into relevant held for sale accounts and completed the asset impairment analysis. It was determined that the assets of Medix were fully impaired. The impact of the impairment analysis resulted in the full impairment of all assets held for sale with a residual liability of $24.8 million reported on the liabilities and accrued impairment held for sale line on the consolidated financial statements. This amount consists primarily of held for sale liabilities inclusive of accrued impairment for liabilities associated with the anticipated realization of deferred losses related to foreign currency changes included within accumulated other comprehensive income. The Company does not believe the sale of Medix constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company's consolidated financial statements and the Company has classified the assets and liabilities as held for sale as of March 31, 2019. Due to the classification of these assets and liabilities as held for sale, the Company recognized a loss of $24.6 million which includes an accrual for the anticipated realization of deferred foreign currency related adjustments in accumulated other comprehensive income of $28.2 million and adjustment of $4.6 million for assets with a book value in excess of their fair market value. |
Basis of Presentation (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (“Natus,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Except where noted below within Note 1, the accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, the reports do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, and reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. The consolidated balance sheet as of December 31, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. |
Recent Accounting Pronouncements | Recent Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02. The new standard provides a number of optional practical expedients in transition. The Company elected the 'package of practical expedients,' which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. The Company has not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to the Company. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off the balance sheet. The Company will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term. The new standard became effective for the Company on January 1, 2019. The Company adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, the Company recognized additional new lease assets of approximately $19.5 million and additional lease liabilities of approximately $22.3 million as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance will not be updated and the disclosures required under the new standard will not be provided for periods prior to January 1, 2019. The adoption of the new standard did not impact the Company's liquidity or debt-covenant compliance under its current agreements. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “2017 Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU is effective for the Company on January 1, 2019. Upon adoption, the Company reclassified its stranded tax effects resulting from the 2017 Act of $1.3 million, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019. In July 2018, the FASB issued ASU 2018-09, Codification Improvements. This update makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standard Codification. The majority of the amendments in ASU 2018-09 will be effective for us in annual periods beginning after December 15, 2018. The adoption of this guidance did not have an impact on the Company's consolidated financial statements. Recent Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Credit Losses (Topic 326). This update requires financial assets measured at amortized cost, such as trade receivables and contract assets, be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. The guidance is effective beginning January 1, 2020. The Company is evaluating the impact, if any, that this pronouncement will have on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate Step 2 from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for the Company's annual and any interim goodwill impairment tests performed on or after January 1, 2020. The Company does not expect the adoption of ASU 2017-04 to have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement (Topic 813), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. This update amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosure. For calendar year-end entities, the update will be effective for annual periods beginning January 1, 2020, and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period. As the standard relates only to disclosures, the Company does not expect the adoption to have a material impact on the consolidated financial statements and is still evaluating if it will early adopt. |
Leases | The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company's leases do not provide an implicit borrowing rate, an incremental borrowing rate is used in determining the present value of lease payments based on information available at commencement date. The Company uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term. Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in the Company's consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet. The Company has lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, the Company accounts for these components separately. For equipment leases, such as office equipment and vehicles, the Company accounts for the lease and non-lease components as a single lease component. |
Revenue (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of contract assets and liabilities | The following table summarizes the changes in the unbilled AR and deferred revenue balances for the three months ended March 31, 2019 (in thousands):
|
Earnings Per Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | The components of basic and diluted EPS are as follows (in thousands, except per share amounts):
|
Inventories (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Inventories | Inventories consist of the following (in thousands):
|
Intangible Assets (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization expense related to intangible assets with definite lives | The following table summarizes the components of gross and net intangible asset balances (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization expense | Amortization expense related to intangible assets with definite lives was as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected amortization expense related to amortizable intangible assets | Expected amortization expense related to amortizable intangible assets is as follows (in thousands):
|
Goodwill (Tables) |
3 Months Ended | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||
Carrying amount of Goodwill | The carrying amount of goodwill and the changes in the balance are as follows (in thousands):
|
Property and Equipment, net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment net | Property and equipment, net consist of the following (in thousands):
|
Reserve for Product Warranties (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Product Warranties Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reserve for Product Warranties | The details of activity in the warranty reserve are as follows (in thousands):
|
Share-Based Compensation (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Expense | Details of share-based compensation expense are as follows (in thousands):
|
Other Income (Expense), net (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income (Expense), net | Other income (expense), net consists of (in thousands):
|
Debt and Credit Arrangements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-term debt | Long-term debt consists of (in thousands):
|
Financial Instruments and Derivatives (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of interest rate swaps | The Company held the following interest rate swaps as of March 31, 2019 (in thousands):
|
Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lease, Cost [Table Text Block] | Components of lease cost were as follows (in thousands):
Supplemental cash flow information related to leases was as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities, Lessee [Table Text Block] | Supplemental balance sheet information related to leases was as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finance Lease, Liability, Maturity [Table Text Block] | As of March 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | As of March 31, 2019, future minimum lease payments included in the measurement of lease liabilities on the consolidated balance sheet, for the following five fiscal years and thereafter, were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | The future minimum commitments under the Company’s leases as of December 31, 2018 were as follows (in thousands):
|
Segment, Customer and Geographic Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue and Long-lived Asset Information by Geographic Region | Revenue and long-lived asset information are as follows (in thousands):
|
Fair Value Measurements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of the derivative financial instrument | The table below presents the fair value of the derivative financial instruments as well as the classification on the consolidated balance sheet (in thousands):
|
Basis of Presentation (Details) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Jan. 01, 2019 |
Dec. 31, 2018 |
---|---|---|---|
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating Lease, Right-of-Use Asset | $ 18,982 | $ 0 | |
Operating Lease, Liability | $ 21,485 | ||
ASU 2016-02 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Operating Lease, Right-of-Use Asset | $ 19,500 | ||
Operating Lease, Liability | 22,300 | ||
ASU 2018-02 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Cumulative effect adjustment | $ 1,300 |
Revenue - Unbilled AR and Deferred Revenue (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Movement in Deferred Revenue [Roll Forward] | |
Deferred Revenue, December 31, 2018 | $ 21,410 |
Additions | 9,143 |
Revenue Recognized | (7,164) |
Deferred Revenue, March 31, 2019 | 23,389 |
Unbilled AR | |
Movement in Unbilled AR [Roll Forward] | |
Unbilled AR, December 31, 2018 | 3,012 |
Additions | 26 |
Transferred to Trade Receivable | 495 |
Unbilled AR, March 31, 2019 | $ 2,543 |
Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Earnings Per Share [Abstract] | ||
Net loss | $ (30,001) | $ (3,148) |
Weighted average common shares (in shares) | 33,590 | 32,760 |
Dilutive effect of stock based awards (in shares) | 0 | 0 |
Diluted Shares (in shares) | 33,590 | 32,760 |
Basic earnings per share (dollars per share) | $ (0.89) | $ (0.10) |
Diluted earnings per share (dollars per share) | $ (0.89) | $ (0.10) |
Diluted earnings per share (in shares) | 119 | 390 |
Inventories (Details) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Summary of Inventories | ||
Raw materials and subassemblies | $ 36,107 | $ 31,459 |
Work in process | 2,424 | 2,424 |
Finished goods | 63,277 | 63,932 |
Total inventories | 101,808 | 97,815 |
Less: Non-current inventories | (18,942) | (18,079) |
Inventories, current | $ 82,866 | $ 79,736 |
Intangible Assets - Schedule of Amortization Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | $ 6,045 | $ 6,878 |
Technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | 1,738 | 1,819 |
Customer related | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | 2,183 | 2,881 |
Trade names | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | 1,498 | 1,626 |
Internally developed software | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | 504 | 530 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | 20 | 22 |
Service Agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total amortization | $ 102 | $ 0 |
Intangible Assets - Schedule of Expected Amortization Expense (Details) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Expected annual amortization expense related to amortizable intangible assets | ||
Nine months ending December 31, 2019 | $ 17,250 | |
2019 | 21,678 | |
2020 | 20,791 | |
2021 | 17,349 | |
2022 | 16,378 | |
2023 | 14,487 | |
Thereafter | 24,272 | |
Net Book Value | $ 132,205 | $ 139,453 |
Goodwill (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Carrying amount of goodwill | |
December 31, 2018 | $ 147,644 |
Foreign currency translation | (254) |
March 31, 2019 | $ 147,390 |
Property and Equipment, net (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
Dec. 31, 2018 |
|
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 68,089 | $ 62,646 | |
Finance Lease, Right-of-Use Asset | 3,064 | 0 | |
Accumulated depreciation | (41,809) | (39,733) | |
Total | 26,280 | 22,913 | |
Depreciation | 1,500 | $ 1,000 | |
Land | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 1,677 | 1,828 | |
Buildings | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 6,184 | 7,036 | |
Leasehold improvements | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 4,703 | 4,649 | |
Equipment and furniture | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 26,879 | 23,487 | |
Computer software and hardware | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 12,936 | 12,803 | |
Demonstration and loaned equipment | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 12,646 | $ 12,843 |
Reserve for Product Warranties - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2019 |
Dec. 31, 2018 |
Mar. 31, 2018 |
Dec. 31, 2017 |
|
Product Warranties Disclosures [Abstract] | ||||
Product warranty period (in years) | 1 year | |||
Product Liability Contingency [Line Items] | ||||
Accrual of estimated costs | $ 8,225 | $ 9,391 | $ 9,068 | $ 10,995 |
Certain products | ||||
Product Liability Contingency [Line Items] | ||||
Accrual of estimated costs | $ 3,200 |
Reserve for Product Warranties - Schedule of Warranty Reserve (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Reserve for Product Warranties | ||
Balance, beginning of period | $ 9,391 | $ 10,995 |
Additions charged to expense | 609 | (1,125) |
Utilizations | (1,511) | (802) |
Changes in estimate related to product remediation activities | (255) | 0 |
Standard and Extended Product Warranty Accrual, Decrease for Divestiture | (9) | 0 |
Balance, end of period | $ 8,225 | $ 9,068 |
Share-Based Compensation - Narrative (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
plan
| |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Number of active share based compensation plans | plan | 2 |
Unrecognized compensation expense related to unvested portion of stock options | $ | $ 15.0 |
Weighted average period of recognition of unrecognized compensation expense | 2 years 6 months |
Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Share-based compensation expense | $ 2,432 | $ 2,362 |
Cost of revenue | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Share-based compensation expense | 67 | 68 |
Marketing and selling | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Share-based compensation expense | 230 | 198 |
Research and development | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Share-based compensation expense | 245 | 276 |
General and administrative | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Share-based compensation expense | $ 1,890 | $ 1,820 |
Other Income (Expense), net (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Other expense, net | ||
Interest income | $ 20 | $ 10 |
Interest expense | (1,527) | (1,960) |
Foreign currency gain (loss) | (598) | 604 |
Other expense | (7) | (475) |
Total other expense, net | $ (2,112) | $ (1,821) |
Debt and Credit Arrangements - Schedule of Long-term debt (Details) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Debt Instrument [Line Items] | ||
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months | $ 0 | $ 0 |
Revolving credit facility | 100,000 | 105,000 |
Debt issuance costs | (478) | (526) |
Less: current portion of long-term debt | 35,000 | 35,000 |
Total long-term debt | 64,522 | 69,474 |
Long-term Debt, Maturities, Repayments of Principal in Year Three | 0 | 0 |
Long-term Debt, Maturities, Repayments of Principal in Year Four | 100,000 | 105,000 |
Long-term Debt, Maturities, Repayments of Principal after Year Five | 0 | 0 |
Revolving credit facility | Line of Credit | ||
Debt Instrument [Line Items] | ||
Revolving credit facility | $ 100,000 | $ 105,000 |
Financial Instruments and Derivatives (Details) |
Mar. 31, 2019
USD ($)
|
---|---|
Derivative [Line Items] | |
Losses associated with cash flow hedge expected to be reclassified within the next 12 months | $ 44,000 |
Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swap | |
Derivative [Line Items] | |
Current Notional Amount | $ 40,000,000 |
Fixed Interest Rate | 2.611% |
Estimated Fair Value | $ 179,000 |
Leases - Narrative (Details) |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Operating Leased Assets [Line Items] | |
Operating Lease, Weighted Average Remaining Lease Term | 4 years 1 month 6 days |
Lessee, Operating Lease, Renewal Term | 10 years |
Minimum | |
Operating Leased Assets [Line Items] | |
Operating Lease, Weighted Average Remaining Lease Term | 1 year |
Maximum | |
Operating Leased Assets [Line Items] | |
Operating Lease, Weighted Average Remaining Lease Term | 8 years |
Leases - Lease Cost (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Leases [Abstract] | |
Operating Lease, Cost | $ 1,765 |
Finance Lease, Right-of-Use Asset, Amortization | 165 |
Finance Lease, Interest Expense | 22 |
Short-term Lease, Cost | 38 |
Variable Lease, Cost | 884 |
Sublease Income | (34) |
Lease, Cost | $ 2,840 |
Leases - Supplemental Cash Flow (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Leases [Abstract] | ||
Operating Lease, Payments | $ 3,493 | |
Finance Lease, Interest Payment on Liability | 37 | |
Finance Lease, Principal Payments | 165 | $ 0 |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | 1,120 | |
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | $ 87 |
Leases - Supplemental Balance Sheet (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Dec. 31, 2018 |
|
Leases [Abstract] | ||
Operating lease right-of-use assets | $ 18,982,000 | $ 0 |
Current portion of operating lease liabilities | 6,251,000 | 0 |
Operating lease liabilities | 15,234,000 | $ 0 |
Operating Lease, Liability | 21,485,000 | |
Finance Lease, Right-Of-Use Asset, Gross | 3,064,000 | |
Finance Lease, Right-Of-Use Asset, Accumulated Depreciation | 1,537,000 | |
Finance Lease, Right-of-Use Asset | 1,527,000 | |
Finance Lease, Liability, Current | 563,000 | |
Finance Lease, Liability, Noncurrent | 1,023,000 | |
Finance Lease, Liability | $ 1,586,000 | |
Operating Lease, Weighted Average Remaining Lease Term | 4 years 1 month 6 days | |
Finance Lease, Weighted Average Remaining Lease Term | 3 years 8 months 12 days | |
Operating Lease, Weighted Average Discount Rate, Percent | 5.30% | |
Finance Lease, Weighted Average Discount Rate, Percent | 5.10% |
Leases - Future Minimum Payments (Details) |
Dec. 31, 2018
USD ($)
|
---|---|
Leases [Abstract] | |
Operating Leases, Future Minimum Payments Due, Next Twelve Months | $ 8,092,000 |
Operating Leases, Future Minimum Payments, Due in Two Years | 6,951,000 |
Operating Leases, Future Minimum Payments, Due in Three Years | 5,290,000 |
Operating Leases, Future Minimum Payments, Due in Four Years | 3,423,000 |
Operating Leases, Future Minimum Payments, Due in Five Years | 2,426,000 |
Operating Leases, Future Minimum Payments, Due Thereafter | 1,365,000 |
Operating Leases, Future Minimum Payments Due | $ 27,547,000 |
Segment, Customer and Geographic Information - Narrative (Details) |
3 Months Ended |
---|---|
Mar. 31, 2019
segment
| |
Segment Reporting [Abstract] | |
Number of reportable segments (segments) | 1 |
Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Long Lived Assets Held-for-sale [Line Items] | ||
Loss on disposal of property and equipment | $ 179 | $ 52 |
Fair Value Measurements - Schedule of Derivative Financial Instruments at Fair Value (Details) - Level II - Recurring $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Derivative Liability [Roll Forward] | |
December 31, 2018 | $ 77 |
Additions | 0 |
Payments | 0 |
Adjustments | 102 |
March 31, 2019 | $ 179 |
Sale of Certain Subsidiary Assets (Details) - USD ($) |
Apr. 02, 2019 |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|---|
Related Party Transaction [Line Items] | |||
Liabilities and accrued impairment held for sale | $ 24,786,000 | $ 0 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | $ (41,239,000) | $ (38,032,000) | |
Subsequent Event [Member] | Medix Medical Devices, SRL [Member] | |||
Related Party Transaction [Line Items] | |||
Related Party Transaction, Amounts of Transaction | $ 2,500 | ||
Notes Receivable, Related Parties | 2,200,000 | ||
Liabilities and accrued impairment held for sale | 24,800,000 | ||
Gain (Loss) on Sale of Assets and Asset Impairment Charges | 24,600,000 | ||
Accumulated Other Comprehensive Income (Loss), Net of Tax | 28,200,000 | ||
Assets, Fair Value Adjustment | $ 4,600,000 |
,5RE9!]:R612W E#D^)6$$!9"BA)%XS-
M](S.L%)S1Y8ZTKPFD^8-'2E9YXS).)+!J8$[ JK MG&:
M'*G,H.,DK[S+P#ZD\4W^P*=I_\IM*[0C5^/Q96/_&V,\8"K)'8Y0AQ]L,20T
M/AS?X]E.8S89WO3S#V++-RY_ U!+ P04 " ";@JA.6%A;"+0! #2 P
M&0 'AL+W=O WPQ-!"^F<6_69XP %!DEC U \6:""<"B$ $8"X98%-!&
M@0&<'9]9R_W"(B'Q:#CQ$BRR.Z9?NOP"WHB?,ZR?O %)#X0/S3=:OK7:]'4D
M 4I>M_ T*ZZ57I6/\(.@PNY):#S%$(;#E8D$M F7S(
MR6
MY*DU [%C[SL1GGASX-B;(CAC*^(=)N_0>\DW-[C;%H7'*S(>M' =W _^I/Q%EM8*JFALQ([
M8J#.Z>W^<$Q#? SX*6&TJS,)E9P1GX+QK'S9V/_*& \H976%(]3@!YL,"94/QQL\
MVV',!L.;=OQ!;/K&^5]02P,$% @ FX*H3A'H?F/3 0 G 0 !D !X
M;"]W;W)K
%6KA'K0N'SQ/;0X\9VHB2EZ8?W9"YDR;H=Q[JI2<;6U0
MGGG4]R,O9VGA+N=V[EDNY^*HL[3@S])1QSQG\M\3S\1YX1+W8^(EW1]T->$M
MYR7;\Y]<_RJ?I1EY++N%DRT D1+9GFK
M,87ZAN6MQA3J*\